| --- | --- | --- | --- | |-------|-------|---------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | Q4 and FY 2021 Financials | | | | | | | | | | | | | | | & Corporate Update | | | | | | | | | | | | | | | | | | | | | | | | | | | Leadership Present At This Earnings Call | --- | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38869 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 81-5395687 (State of Other Jurisdiction of incorporation or Organizat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________. Commission File Number: 001-38869 HOOKIPA PHARMA INC. (Exact Name of Registrant as Specified in its ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________. Commission File Number: 001-38869 HOOKIPA PHARMA INC. (Exact Name of Registrant as Specified in its Chart ...

Supercharging Immunotherapy June 2021 Disclaimer This presentation and other related material may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding HOOKIPA's expectation about any or all of the following: (i) the success, cost and timing of HOOKIPA's product development activities and clinical trials; (ii) the timing, scope or likelihood of regulatory filings and approvals, including timing ...

Supercharging Immunotherapy May 2021 Disclaimer This presentation and other related material may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding HOOKIPA's expectation about any or all of the following: (i) the success, cost and timing of HOOKIPA's product development activities and clinical trials; (ii) the timing, scope or likelihood of regulatory filings and approvals, including timing o ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the quarterly period ended March 31, 2021 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) Commission File Number: 001-38869 (I.R.S. Employer Identification No.) HOOKIPA PHARMA INC. Registrant's telephone number, including area code: +43 1 890 63 60 Securities registered pursuant to Section 12(b) of the Act: OR (Exact Name of Registrant as Specified in its ...

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Q4 2020 Results Conference Call March 18, 2021 8:30 AM ET Company Participants Matthew Beck - Head of Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Officer Igor Matushansky - Chief Medical Officer and Head of Global Research and Development Christine Baker - Chief Business Officer Roman Necina - Chief Technology Officer Conference Call Participants Alec Stranahan - Bank of America Securities Ingrid Gafanhão - Kempen Roy Buchanan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 81-5395687 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Identification No.) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 350 Fifth Avenue, 72nd Floor, Suite 7240 For the fiscal year ended December 31, 2020 New York, New York (Address of principal exec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________. Commission File Number: 001-38869 HOOKIPA PHARMA INC. (Exact Name of Registrant as Specified in its ...